Neal D. Shore, MD (he/him/his)

Neal D. Shore, MD, FACS
Director, CPI, Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina

Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with GenesisCare in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 400 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Board of theSociety of Urologic Oncology . He serves as the National Urology Research Director for GenesisCare,US, the co-chair for the Global Prostate Cancer Research Council, GenesisCare and the co-chair of teh AUA International Prostate Forum. He has served on the AUA Male Health Committee,the AUA Data Committee, AUA Innovations Committee, AUA Research Committee,the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE(Academic Editor), Urology Practice, and serves as Editor, Everyday Urology. He has more than 200 peer reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, European Urology,Journal Urology, Urology, BJUI,PCPD, and numerous other high impact scientific journals.
A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6 month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.

Disclosure information not submitted.

Presentation(s):

• MP11-14: Treatment duration and long-term safety and tolerability with darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): ARAMIS Rollover Study

  Friday, April 28, 2023
  9:30 AM – 11:30 AM CST

• MP29-02: Efficacy and Safety of Darolutamide in Combination with Androgen-deprivation Therapy and Docetaxel in the North American Population from ARASENS

  Saturday, April 29, 2023
  7:00 AM – 9:00 AM CST

• MP29-05: Treatment Pattern and Health-Related Quality of Life (HRQoL) of Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the United States (US)

  Saturday, April 29, 2023
  7:00 AM – 9:00 AM CST

• MP29-13: Real-world Study on Darolutamide, Enzalutamide, and Apalutamide for Nonmetastatic Castration-Resistant Prostate Cancer Patients Using a Urology Network in the United States (DEAR Study)

  Saturday, April 29, 2023
  7:00 AM – 9:00 AM CST

• Session Five: Collaboration with Academic Institutions and International

  Saturday, April 29, 2023
  10:35 AM – 10:37 AM CST

• Q&A with Session Speakers

  Saturday, April 29, 2023
  11:13 AM – 11:20 AM CST

• EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-Risk Biochemically Recurrent Prostate Cancer

  Saturday, April 29, 2023
  9:45 AM – 10:00 AM CST

• PD21-11: REAL WORLD IMPACT OF GERMLINE GENETIC TESTING ON CLINICAL DECISION MAKING FOR PROSTATE CANCER PATIENTS

  Saturday, April 29, 2023
  2:30 PM – 2:40 PM CST

• Enhancing the Treatment of High-Risk Non-Muscle Invasive Bladder Cancer With Immunotherapy-Based Regimens

  Saturday, April 29, 2023
  6:00 PM – 8:00 PM CST

• International Prostate Forum Introductions

  Sunday, April 30, 2023
  8:01 AM – 8:05 AM CST

• Challenge VII: Updates in Advanced Prostate Cancer

  Sunday, April 30, 2023
  11:45 AM – 12:45 PM CST

• Optimal TURBT: Do Skilled Urologists Really Need PDD?

  Sunday, April 30, 2023
  2:30 PM – 2:50 PM CST

• Beyond The Guidelines: Urologic Oncology Investigators Provide Perspectives on the Optimal Management of Prostate Cancer

  Sunday, April 30, 2023
  5:30 PM – 8:00 PM CST